Back to search
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Clinicaltrials.gov:
EU CTIS:
#2025-522007-18-00
Other:
#79635322MMY3001
Interested in this trial?
Subscribe or share this trial
Trials at a glance
Status
Enrolling
Condition
Multiple Myeloma
Trial type
Interventional
Trial phase
Phase 3
Investigational
product
product
JNJ-79635322
Teclistamab
Age
18+ years old
Biological sex
All
Placebo?
No
Trial start date
February 4, 2026
Trial end date
September 30, 2031
CT.gov ID
#NCT07258511
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
Countries:
- Australia,
- Canada,
- Germany,
- Greece,
- Israel,
- Japan,
- Netherlands,
- Norway,
- United Kingdom,
- United States
Loading...
Enrolling
Calgary, Alberta, Canada, T2N 4N1
Enrolling
Tel Aviv, Israel, 69710
Enrolling
Ramat Poriya, Israel, 1520800
Enrolling
Dallas, Texas, United States, 75246
Enrolling
Haifa, Israel, 31048
Enrolling
Box Hill, Australia, 3128
Enrolling
Montreal, Quebec, Canada, H1T 2M4
Enrolling
Cardiff, United Kingdom, CF14 4XW
Enrolling
Haifa, Israel, 34362
Enrolling
Chiba, Japan, 260 0801
Enrolling
Denver, Colorado, United States, 80218
Enrolling
Durham, North Carolina, United States, 27705
Enrolling
Atlanta, Georgia, United States, 30322
Enrolling
Rotterdam, Netherlands, 3015
Enrolling
Athens, Greece, 106 76
Enrolling
Murdoch, Australia, 6150
Enrolling
Fort Myers, Florida, United States, 33901
Enrolling
Southport, Australia, 4215
Enrolling
The Hague, Netherlands, 2545 AA
Enrolling
Salt Lake City, Utah, United States, 84112
Enrolling
New York, New York, United States, 10029
Enrolling
Shibuya City, Japan, 150-8935
Enrolling
Hamilton, Ontario, Canada, L8V5C2
Enrolling
Kamogawa, Japan, 296-8602
Enrolling
Yokohama, Japan, 241 8515
Enrolling
Canterbury, United Kingdom, CT1 3NG
Enrolling
New York, New York, United States, 10016
Enrolling
London, Ontario, Canada, N6A 5W9
Enrolling
Düsseldorf, Germany, 40479
Enrolling
Brisbane, Australia, 4101
Enrolling
New York, New York, United States, 10065
Enrolling
Waukee, Iowa, United States, 50263
Enrolling
Tampa, Florida, United States, 33612
Enrolling
Clayton, Australia, 3168
Enrolling
Brooklyn, New York, United States, 11234
Enrolling
New York, New York, United States, 10011
Enrolling
Mineola, New York, United States, 11501
Enrolling
Dundee, United Kingdom, DD1 9SY
Enrolling
Louisville, Kentucky, United States, 40207
Enrolling
Portland, Oregon, United States, 97239
Enrolling
Halifax, Nova Scotia, Canada, B3H 3A7
Enrolling
Haifa, Israel, 3109601
Enrolling
Nashville, Tennessee, United States, 37203
Enrolling
Jerusalem, Israel, 9103102
Enrolling
Ramat Gan, Israel, 52621
Enrolling
Kamakura-shi, Japan, 247-8533
Enrolling
Nedlands, Australia, 6009
Enrolling
Beersheba, Israel, 8457108
Enrolling
Fitzroy, Australia, 3065
Enrolling
Austin, Texas, United States, 78704
Enrolling
Trondheim, Norway, 7030
Enrolling
Melbourne, Australia, 3004
Enrolling
Minato, Japan, 105-8471
Enrolling
Thessaloniki, Greece, 546 39
Enrolling
Philadelphia, Pennsylvania, United States, 19107
Enrolling
Bunkyō City, Japan, 113 8677
Enrolling
Los Angeles, California, United States, 90033
Enrolling
Jena, Germany, 07747
Enrolling
London, United Kingdom, NW1 2PG
Enrolling
Toronto, Ontario, Canada, M5G 2M9
Enrolling
Farmington, Connecticut, United States, 06030
Enrolling
Iowa City, Iowa, United States, 52242
Enrolling
Amsterdam, Netherlands, 1081 HV
Enrolling
New Haven, Connecticut, United States, 06510
Enrolling
Kofu, Japan, 400-0027
#
More than 50 sites in this region
#
More than 10 sites in this region
#
Less than 10 sites in this region
Individual sites
Access detailed information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2026
